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Abstract
Background: Paratuberculosis remains today a major global problem in animal health, especially for dairy cattle.
However, the diagnosis of its etiologic agent, Mycobacterium avium subsp. paratuberculosis (Map), still lacks
sensitivity because of the lack of available antigens. Little is known about the virulence factors for this pathogen. In
this study we have developed a method to produce and purify the heparin-binding hemagglutinin (HBHA), a major
adhesin of Mycobacteria, from a culture of Map.
Findings: For this extremely slow-growing Mycobacterium, a culture was established in a 3-liter bioreactor. Using
the bioreactor the amount of the Map biomass was increased 5-fold compared to a classical culture in flasks. The
map-HBHA was purified from a Map lysate by heparin-Sepharose chromatography on HiTrap columns. Binding of
map-HBHA onto heparin-Sepharose can be reduced in the presence of salt. Consequently, all steps of sample
preparation and column equilibration were carried out in 20 mM Tris–HCl (pH 7.2). The map-HBHA was eluted by a
linear NaCl gradient. High resolution mass spectrometry analyses revealed that the native form of map-HBHA has
posttranslational modifications, including the removal of the initiation methionine, acetylation of the alanine residue
at the N-terminal extremity and the presence of methylated lysines in the C-terminal domain of the protein.
Conclusions: An optimized culture of Map in a bioreactor was established to purify the native map-HBHA from a
Map lysate by heparin-Sepharose chromatography. The availability of this antigen offers the possibility to study the
structure of the protein and to examine its role in pathogenicity, in particular to better understand the specific
interactions of Map with the intestinal tissue. The map-HBHA obtained in its native immunogenic form may also be
useful to improve the diagnostic test, especially for the development of a new T-cell-based interferon gamma
release assays.
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Findings
Background
Mycobacterium avium subsp. paratuberculosis (Map) is
the etiologic agent of a severe granulomatous inflamma-
tory bowel disease in ruminants, known as Johne’s dis-
ease or paratuberculosis [1,2]. This enzootie remains
today a major animal health problem with a high global
prevalence causing significant economic losses in the
cattle industry [2-6]. One characteristic feature of Map
is its adaptation to the gastrointestinal tract of rumi-
nants. However, the molecular and cellular mechanisms
of its interactions with M cells [7] and epithelial cells [8]
are not yet fully elucidated. Mycobacterium-epithelium
interactions, much better studied with Mycobacterium
tuberculosis, involve an adhesin called heparin-binding
hemagglutinin (HBHA), which plays a crucial role in the
binding of the mycobacteria to epithelial cells and other
non-phagocytic cells [9,10]. HBHA is an adhesin that
binds sulphated carbohydrates, such as heparin and
heparan sulfate, present on the surface of various
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lysine-rich motifs [11]. Native HBHA from M. tubercu-
losis carries methyl groups added post-translationally,
which are important for its antigenicity [12]. Several
investigations have demonstrated that a HBHA-specific
IFN- γ response, indicative of latent M. tuberculosis in-
fection and protective immunogenicity depends on the
methylation of the antigen [13-16].
Comparative genomics suggests that HBHA is also
present in Map. In order to study the biochemical char-
acteristics of the HBHA from Map (map-HBHA) and to
evaluate its potential in diagnostics and vaccine develop-
ment, it is essential to have access to native map-HBHA.
Our first attempts to purify map-HBHA by heparin-
Sepharose chromatography under conditions used to
purify HBHA from M. tuberculosis failed to isolate the
map-HBHA. In addition, the purification was hampered
by the difficulty to obtain sufficient biomass of Map due
to the extremely slow growth of this microorganism.
In this study we established a new method of Map cul-
ture, using a bioreactor, which substantially increased
the biomass yield and shortened the time of culture. In
addition, we describe a new purification procedure,
which led to the isolation of native map-HBHA.
Results and discussion
Optimization of Map biomass production in a bioreactor
Map is one of the slowest-growing Mycobacteria with a
mean generation time of 1.38 days [17]. Map cultures
thus require long time periods with limited opportun-
ities for recording and correcting parameters. Further-
more, the final product of these cultures was shown to
contain high proportions of dead bacilli that may reduce
the quality of the proteins harvested [18]. To circumvent
these difficulties, we chose to investigate the growth of
Map in a bioreactor to increase the biomass, standardize
the culture conditions and control potential contamina-
tions. Previous studies using bioreactors have described
the standardization of M. bovis BCG cultures for vaccine
production [19,20]. Growth of Map in a bioreactor was
compared to conventional culture flasks inoculated in
parallel with the same Map pre-culture at an OD600nm of
0.06. After 40 days, the cultures were centrifuged and
the harvested biomasses were weighed. As shown in
Figure 1, the biomass harvested from the bioreactor was
significantly more important in comparison to the con-
ventional culture in flasks. Using the bioreactor we
obtained, as an average of three independent experi-
ments, five times more bacteria than with flask cultures
(4 versus 20 g L-1).
Protein purification
Our first attempts to purify map-HBHA by heparin-
Sepharose chromatography under conditions used to pur-
ify HBHA from M. tuberculosis have been unsuccessful.
This may be due, at least partly, to the nature of the pro-
tein. Although the alignment of the HBHA amino acid
sequences from different mycobacterial species indicates
that these molecules are highly conserved, the C-terminal
lysine-rich domain is rather divergent (Figure 2A). These
differences may modify the affinity of the proteins for the
heparin-coupled matrix, due to the differences in the dis-
tribution of the positively charged lysines involved in the
cation- and anion-exchange chromatography (Figure 2B).
In a previous study, we have shown that the isolation of
the M. smegmatis HBHA requires a modification of the
elution parameters, as its C-terminal end is less positively
charged, compared to that of the M. tuberculosis HBHA
[21]. As indicated in Figure 2B, the C-terminal sequence
of the map-HBHA contains one acidic residue and 9 posi-
tively charged lysines compared to 14 positively charged
lysines in HBHA from M. tuberculosis. The predicted iso-
electric point (7) is lower than that calculated for HBHA
of M. tuberculosis (9.6) or M. smegmatis (8.8), suggesting
that the binding and elution parameters have to be
adjusted. Because of the slow growth of Map, the chroma-
tography conditions were first established with a recom-
binant form of map-HBHA producing in E. coli.
Heparin-sepharose column
First, a lysate of recombinant E. coli producing map-
HBHA was applied onto two types of heparin-Sepharose
columns in 0.5 × PBS: the prepacked HiTrap column or
heparin-Sepharose CL6B poured into a Pharmacia col-
umn. As shown in Figure 3, the recombinant map-
Biomass
g L-1
Flask Bioreactor
Figure 1 Increasing biomass production using a bioreactor.
Cultures of Map K-10 (ATCC BAA-968) in flask or bioreactor were
inoculated with a pre-culture at an OD600 nm of 0.06. Both cultures
were maintained at 37°C during 40 days under agitation and air in
the bioreactor and under static conditions in the flask. The bacteria
were harvested by centrifugation and the biomasses were weighed.
The figure represents the average of three independent experiments
(+/− standard deviations).
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HBHA was successfully purified from a lysate of E. coli.
It was eluted from the heparin-Sepharose column at low
salt concentrations, starting from 100 mM NaCl. Al-
though both columns showed similar performances with
a lysate containing large amounts of recombinant map-
HBHA, the HiTrap column, more reproducible in our
hands, was preferred.
Buffer conditions
Surprisingly, when the supernatant of a whole-cell lysate
of Map was subjected to purification under the conditions
established for recombinant map-HBHA, the native map-
HBHA was not isolated. As shown in Figure 4 in late elu-
tion fractions only one protein corresponding to Lbp/Hlp,
A
Mtb    MAEN--SNIDDIKAPLLAALGAADLALATVNELITNLRERAEETRTDTRSRVEESRARLTKLQEDLPEQLTELREKFT---------AEELRKAAEGYLEAATSRYNELVERGEAA 105
BCG    MAEN--SNIDDIKAPLLAALGAADLALATVNELITNLRERAEETRTDTRSRVEESRARLTKLQEDLPEQLTELREKFT---------AEELRKAAEGYLEAATSRYNELVERGEAA 105
Mah MAEN--PNIDDLRAPLLAALGAADLALATVNDLIANLRERAEETRAETRTRVGERRARLTKFQEDLPEQFTELRDKFT---------TEELRKAAEGYLEAATNRYNELVERGEAA 105
Map    MAEN--PNIDDLRAPLLAALGAADLALATVNDLIANLRERAEETRAETRTRVEERRARLTKFQEDLPEQFTELRDKFT---------TEELRKAAEGYLEAATNRYNELVERGEAA 105
Msmeg  MADKTQPTVEELKAPLLAAVGAADLALATVNEIIATLLERAGEARSDAEARVEESRARLTKLQEELPSQFGELREKLNSDELRKKLNSEELRKAAESYADQATATYNKLVERGEAA 107
**::  ..:::::******:***********::*:.* *** *:*:::.:** * ******:**:**.*: ***:*:.         :********.* : **  **:********
Mtb    LERLRSQQSFEEVSARAEGYVDQAVELTQEALGTVASQTRAVGERAAKLVGIELPKKAAPA-KKAAPA----------------KKAAPAKKAAAKKAP-----AKKAAAKKVTQK 199
BCG    LERLRSQQSFEEVSARAEGYVDQAVELTQEALGTVASQTRAVGERAAKLVGIELPKKAAPA-KKAAPA----------------KKAAPAKKAAAKKAP-----AKKAAAKKVTQK 199
Mah LQRLRSQTAFEDASARAEGYVDQAVELTQEALGTVASQTRAVGERAAKLVGIELPGKAEAAGKKAQKA----------------IAKAPAKKAPAKKAPAKKAPAKKAAAKKVTQK 205
Map    LQRLRSQTAFEDASARAEGYVDQAVELTQEALGTVASQTRAVGERAAKLVGIELPGKAEAAGKKAQKA----------------IAKAPAKKAP---------------AKKVTQK 190
Msmeg  LERLRNQPALEEAATRVETYTDQAVELTQEALGTVASQTRAVGERAAKLVGVELPKRAEAAAETASEAAAETAEPVKKAAAPAAKKAAPAKKAAPAKKATPAKSAAKAPAKKVTQK 232
*:***.* ::*:.::*.* *.******************************:*** :* .* :.*  *                   ******.               *******
B
Mtb ELP++----++----++----++---++---++---++VTQK                        (9.6)
BCG ELP++----++----++----++---++---++---++VTQK                        (9.6)
Mah ELP-+-E---++--+---+---++---++---++---++---++VTQK                  (10.2)
Map ELP-+-E---++--+---+---++---++VTQK                                 (7)
Msmeg ELP++-E---E---E---E--E--++------++----++----++----+---+---++VTQK  (8.8)
Figure 2 Sequence alignment of different HBHA proteins. (A) Multiple sequence alignment was performed using the Clustal W program with
the BLOSUM64 matrice allowing gaps (−). * indicate identical residues. : indicate conserved substitutions. ; indicate semi-conserved substitutions.
Mtb, M. tuberculosis; BCG, M. bovis BCG; Mah, M. avium subsp. hominissuis and Map, M. avium subsp. paratuberculosis; Msmeg, M smegmatis. (B)
Distribution of charges within the C-terminal domain of HBHA. The isoelectric point of each protein is indicated in brackets. Color code: Polar
charged residues HKR (Pink); Polar residues GNQSTY (Green); Polar negative residues DE (Blue) and other residues (Red).
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Figure 3 Heparin-Sepharose chromatography of recombinant
map-HBHA produced in E. coli. A culture of recombinant E. coli
producing map-HBHA was sonicated in 0.5 × PBS. The soluble
material was loaded onto a heparin-Sepharose HiTrap column and
eluted using a 0-1 M NaCl gradient. Whole cell lysate (WCL), flow-
through material (FT) and eluted material were analyzed by SDS-
PAGE. The fractions eluted between 100 and 350 mM NaCl
contained map-HBHA as determined by HR-MS/MS. The molecular
weights (MW) expressed in kDa are indicated in the left margin.
MW WCL     5     10     15      20     25     30       35 
NaCl concentration 
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Figure 4 Heparin-Sepharose chromatography of a Map lysate
in PBS buffer. A Map K-10 culture obtained using the bioreactor
was centrifuged and the pellet was resuspended in 0.5 × PBS. The
bacteria were then sonicated and centrifuged. The whole cell lysate
(WCL) was applied onto a heparin-Sepharose HiTrap column and
eluted using a 0-1 M NaCl gradient. WCL and the indicated elution
fractions were analyzed by SDS-PAGE. Fractions 20 to 25, eluted
around 500 mM NaCl, contained map-Lbp/Hlp, as determined HR-
MS/MS. The molecular weights (MW) expressed in kDa are indicated
in the left margin.
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previously described to bind heparin with strong affinity
[22], was eluted at 500 mM NaCl in this study. These
results suggest that binding and elution parameters need
to be changed to isolate native map-HBHA. The 0.5 ×
PBS loading buffer was thus replaced by a 20 mM Tris–
HCl (pH 7.2) buffer to reduce the presence of salt that can
inhibit the binding of the protein to the matrix. The map-
HBHA prepared in 20 mM Tris–HCl (pH 7.2) was able to
efficiently bind the heparin-Sepharose matrix and was
eluted at approximately 200 mM NaCl (Figure 5). The
early elution of map-HBHA in the NaCl gradient sug-
gests a relationship between the number of positive
charges in the protein and the binding force to the sul-
fated sugars. As indicated in Figure 5, Lbp/Hlp eluted
later, at 500 mM NaCl.
Mass spectrometry analysis
To ascertain the identities of the proteins eluted from hep-
arin-Sepharose, High Resolution tandem Mass Spectrometry
(HR-MS/MS) analyses using a bottom-up approach GeLC-
MS/MS were carried out. These analyses confirmed that the
25-kDa protein eluted at 200 mM NaCl corresponds to
map-HBHA and that the 31-kDa protein eluted at 500 mM
NaCl corresponds to map-Lbp/Hlp. In addition, HR-MS/
MS also revealed important characteristics of the native pro-
teins purified from the Map culture (Table 1). Similar to the
M. tuberculosis HBHA [23], native map-HBHA contains no
initiation methionine at its N-terminus and that the first
amino acid is thus an alanine residue. The cleavage of the
initiation methionine is a post-translational common process
in Mycobacteria [24,25]. The HR-MS/MS analyses also indi-
cated that the amino-terminal alanine is acetylated. This
post-translational modification already reported for other
mycobacterial proteins may be an important regulator of
protein functions [26,27].
Another feature of native map-HBHA, revealed by
HR-MS/MS, is the presence of methylated amino acids
as indicated in Figure 6 and Table 1. Among the pep-
tides analyzed in this study, the lysine residues 154 and
168 were mono-methylated. Other proteomic analyses
are necessary to determine the complete methylation
profile of the HBHA produced by Map. Although the
exact role of the methylation remains to be elucidated,
this post-translational modification was shown to be
crucial for the immunogenicity of the M. tuberculosis
HBHA. Only the native, methylated protein is able to in-
duce strong IFN-γ secretion by peripheral blood mono-
nuclear cells from latently infected human [14] and
when administered in combination with strong Th1-
promoting adjuvants only the methylated form was able
to confer protection against M. tuberculosis in mouse
models [16].
Altogether these data highlight the importance of hav-
ing access to proteins in their native form with their spe-
cific post-translational modifications to understand their
function, their location and to envisage their use as anti-
gens for diagnostics or vaccine development.
Conclusions
The objective of this study was to develop the conditions
that allow us to purify native HBHA from a lysate of Map.
To obtain sufficient biomass of Map, for which the culture
is slow and tedious, a bioreactor culture method was devel-
oped. Under these conditions it was possible to obtain a
biomass of 20 g per liter of culture, a 5-fold higher yield
than in traditional culture conditions. Native map-HBHA
was purified by heparin-Sepharose chromatography.
HiTrap columns gave the best and most reproducible
results. Due to the specific chemical characteristics of na-
tive map-HBHA, in particular the charges present in the
C-terminal part of the protein, the Map lysate had to be
prepared in 20 mM Tris–HCl (pH 7.2) to allow for optimal
binding of map-HBHA to the heparin-Sepharose matrix.
97
66
45
14
31
21
MW     WCL     F11       F28kDa
Figure 5 Native map-HBHA purified by heparin-Sepharose
chromatography in Tris–HCl buffer. Using a 20 mM Tris-HCl
(pH 7.2) buffer a whole cell lysate (WCL) of Map was subjected to
heparin-Sepharose HiTrap chromatography. SDS-PAGE analysis
showed that the material eluted in fraction 11 at ca. 200 mM NaCl
contains map-HBHA, as determined by HR-MS/MS. The map-Lbp/Hlp
was identified in fraction 28, eluted at ca. 500 mM NaCl. The
molecular weights (MW) expressed in kDa are indicated in the
left margin.
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HR-MS/MS analyses revealed post-translational modifica-
tions, such as presence of an acetyl alanine residue at the
N-terminus and methyl-lysines in the C-terminal part of
the protein. In this study, we have thus optimized the Map
culture conditions and the purification of native map-
HBHA, which is therefore now available for structure-
function studies and investigations for use in diagnosis or
vaccine development against Map.
Methods
Bacterial strains, growth conditions and DNA manipulations
Mycobacterium avium subsp. paratuberculosis (Map)
strain K-10 (ATCC BAA-968) was grown at 37°C in
Sauton medium supplemented with 2 mg L-1 of mycobac-
tin J (IDVET, Montpellier, France). E. coli TOP10 (Invitro-
gen Carsbad, CA) and E. coli BL21(DE3) (Novagen,
Darmstadt, DE) were grown in LB medium supplemented
with 50 μg mL-1 kanamycin as appropriate. Restriction
enzymes, T4 DNA ligase and other molecular biology
reagents were purchased from New England Biolabs,
Roche or Promega. PCRs were performed using a Bio-Rad
thermal cycler model iCycler and the PCR products were
sequenced by GenomExpress (Grenoble, France).
Cultivation of Map K-10 in bioreactor
A Map K-10 pre-culture was prepared in Sauton medium
to obtain an initial optical density at 600 nm of 0.06. This
was then inoculated either in 175 cm2-Greiner Bio-one
Flasks maintained at 37°C in static conditions or in a 3-
liter bioreactor (Setric Génie Industriel, Toulouse, France)
constantly kept at 37°C with a stirring rate at 110 rpm and
12 L h-1 of air. During growth, serial time samplings were
performed to determine absorbance at 600 nm. Once the
stationary phase was reached, the bacteria were harvested
by centrifugation at 7,000 × g for 15 min at 4°C and stored
at −20°C until use.
Protein purification by heparin-Sepharose chromatography
A frozen Map pellet corresponding to 5 g was thawed,
washed twice with 0.5 × PBS or 20 mM Tris–HCl
(pH 7.2) and heated at 80°C during 30 min. Heat-killed
bacteria were centrifuged at 10,000 × g for 20 min. The
Map pellet was resuspended in 45 mL 0.5 × PBS or 20
mM Tris–HCl (pH 7.2) and sonicated intermittently in a
Kimble HS N°45500-30 tube using a Branson Sonifier
250D for 20 min repeated 4 times, on ice. The soluble
material obtained after centrifugation at 13,000 × g for
20 min at 4°C was filtered at 0.45 μ and applied onto the
heparin-Sepharose matrix.
All chromatographic steps were carried out on the
Biologic chromatography system (BioRad), at room
temperature and the absorbance at 280 nm was con-
tinuously monitored during the purification. Two
types of columns were investigated. One protocol
used the HiTrap Heparin HP (1 mL, GE Healthcare)
column (0.7 × 2.5 cm) prepacked with heparin-
Sepharose. In the second protocol 1 g of heparin
Sepharose CL-6B (GE Healthcare) resuspended in
5 mL of 0.5 × PBS or 20 mM Tris–HCl (pH 7.2) was
poured into a 1.5 × 10 cm column (Pharmacia), accord-
ing to the recommendations of the supplier. The
columns were washed with 100 mL of 0.5 × PBS or
Table 1 Identification of map-HBHA by mass spectrometry analysis
Peptides identified by HR-MS/MS Peptide position start - end Peptide modification
2AacENPNIDDLR
11 2-11 Acetylated
60FQEDLPEQFTELR72 60-72
73DKFTTEELR81 73-81
82KAAEGYLEAATNR94 82-94
83AAEGYLEAATNR94 83-94
109LRSQTAFEDASAR121 109-121
111SQTAFEDASAR121 111-121
111SQTAFEDASARAEGYVDQAVELTQEALGTVASQTR 145 111-145
122AEGYVDQAVELTQEALGTVASQTR145 122-145
151AAKmeLVGIELPGK
162 151-162 Methylated
154LVGIELPGK162 154-162
154LVGIELPGKAEAAGKme
168 154-168 Methylated
154LVGIELPGKAEAAGKK169 154-169
Peptides highlighted onto sequencea
MAacENPNIDDLRAPLLAALGAADLALATVNDLIANLRERAEETRAETRTRVEERRARLTKFQEDLPEQFTELRDKFTTEELRKAAEGYLEAATNRYNELVERGEAALQRLR
SQTAFEDASARAEGYVDQAVELTQEALGTVASQTRAVGERAAKmeLVGIELPGKAEAAGKmeKAQKAIAKAPAKKAPAKRVTQK.
aThe 13 peptides identified by HR-MS/MS, text in italic, correspond to 52% of sequence coverage.
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20 mM Tris–HCl (pH 7.2) until the absorbance at
280 nm was close to 0. The bound material was
eluted by a 0-1 M NaCl linear gradient using a flow
rate maintained at 0.6 mL min-1 and automatically
collected in 1 mL fractions. Whole cell lysates, flow-
through material and eluted fractions were analyzed
by 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) performed according to
Laemmli [28].
Cloning, sequencing and production of recombinant map-
HBHA in E. coli
The map-HBHA-encoding gene (MAP3968) was ampli-
fied by PCR from chromosomal DNA using the Taq
DNA polymerase (Promega) and two synthetic oligonu-
cleotides (Sigma) with the following sequences: 50- TAT
ACATATGACCATGGCGGAAAACCCGAACATCG -30
and 50- ATATAAGCTTGGTACCCACGAGGTGGTTC
ACGCC -30, containing NdeI and HindIII sites
(underlined). The fragment was amplified after a short
denaturation cycle of 3 min at 95°C by using 35 cycles as
follows: 95°C for 30 s, 57°C for 30 s, and 72°C for 30 s with
a final elongation cycle at 72°C for 10 min. The PCR prod-
uct containing the map-HBHA-coding sequence was
digested by NdeI and HindIII and then inserted into pET-
24a(+) (Novagen), generating pET::map-HBHA. This
plasmid was used to transform E. coli TOP 10 for se-
quencing and E. coli BL21(DE3) for protein expression.
After transformation, E. coli BL21(DE3) cells were
grown at 37°C in 250 mL LB broth supplemented with
50 μg mL-1 kanamycin. At an OD600 of 0.5, IPTG was
added to a final concentration of 1 mM, and growth
was continued for 4 h. The culture was then centrifuged
at 7,000 × g for 15 min at 4°C. The pellet obtained was
stored at −20°C until applied onto heparin Sepharose as
described above.
The GenBank accession numbers for the map-
HBHA (strains K-10 and ATCC19698) sequences are
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
Ab
un
da
nc
e
842.4734
270.1812185.1648
143.1179
213.1598300.1552
421.7399 1084.5999
955.5570
360.2240 560.3042 1254.7043625.3299 745.4199512.3076
688.3986 824.4619
1197.6864 1353.7816
y1
y9
y5
y4
y3y2
y8
y7
y6 y13
y14y12
y10
y11
b2
b3
b6b5
b4
LVGIELPGKAEAAGK*
Figure 6 Fragmentation spectrum of the HBHA 154LVGIELPGKAEAAGK168 peptide with post-translational modification. Shown is a
spectrum obtained by nanoLC-MS/MS analysis with HCD fragmentation mode using LTQ Velos Orbitrap mass spectrometer. The precursor ion
had an m/z 733.93 in charge state 2. The peptide sequence was obtained by all y ions (y1 to y14) and 5 consecutive b ions (b2 to b6). Moreover,
the Δm = +14 Da on the K*168 indicated the presence of a methylation.
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[mapK10_HBHA JX536266 and map19698_HBHA
JX536267].
Identification of the purified Map proteins by high
resolution mass spectrometry analysis
Proteins were digested in-gel with trypsin as previously
described [29]. Peptides were analyzed by nanoLC-MS/
MS using an UltimateW 3000 RSLC coupled to a LTQ
Velos Orbitrap Mass Spectrometer. Samples were loaded
onto a trap column (Acclaim PepMap 100 C18, 100 μm
inner diameter × 2 cm) at a flow rate of at 5 μL min-1
with 4% solvent B (0.1% formic acid, 15.9% water, 84%
acetonitrile) and 96% solvent A (0.1% formic acid, 97.9%
water, 2% acetonitrile). Peptides were fractionated using
a nano-column (Acclaim PepMap C18, 75 μm inner
diameter × 15 cm), with a nanoflow rate of 300 nl min-1
by applying a gradient of 4-55% B for 60 min. The LTQ
Velos Orbitrap instrument was operated in a data-
dependent mode with R = 30,000. In the scan range of
m/z 300–1800, the 10 most intense peptide ions with
charge states ≥2 were isolated for HCD fragmentation.
Raw data files were converted to MGF. The data were
searched against nr NCBI database (Eubacteria) using
MASCOT search engine (version 2.3). Carbamido-
methylcysteine was set as a fixed modification, and oxi-
dation of methionine, N-terminal acetylation and
methylation of lysine were set as variable modifications.
Two missed cleavages were allowed. The tolerance of
the ions was set to 10 ppm for parent and 0.1 Da for
fragment ion matches. Mascot results were subjected to
the Scaffold 3 software (version 3.2). Peptide identifica-
tions were accepted if they could be established at a
greater than 95.0% probability as specified by the Peptide
Prophet algorithm [30]. Protein identifications were
accepted if they could be established at a greater than
99.0% probability and contained at least two identified
peptides [31]. Identified post-translational modifications
were validated using Scaffold PTM (version 2.0).
Localization sites were accepted if they could be estab-
lished at a greater than 99% probability as specified by
the Ascore algorithm [32].
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